Profil
Eric J.
Dadey worked as a Vice President-Drug Delivery at Atrix Laboratories, Inc. and TOLMAR Therapeutics, Inc. He was a Team Leader at Abeona Therapeutics, Inc. and a Senior Vice President-Pharmaceutical Development at Aquestive Therapeutics, Inc. He also worked as a Group Leader at Nycomed Salutar, Inc. and as a Vice President-Preclinical Development at Insmed Ltd.
Prior to his industry career, he was a Faculty Member at the University of Illinois.
He received his undergraduate and graduate degrees from the University of Western Kentucky and his graduate and doctorate degrees from the University of Kentucky.
Ehemalige bekannte Positionen von Eric J. Dadey
| Unternehmen | Position | Ende |
|---|---|---|
Transave, Inc.
 Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Corporate Officer/Principal | 30.08.2012 |
Atrix Laboratories, Inc.
 Atrix Laboratories, Inc. Pharmaceuticals: OtherHealth Technology Atrix Laboratories, Inc. develops and manufactures dental, medical, and veterinary products for drug delivery application | Corporate Officer/Principal | - |
Insmed Ltd.
 Insmed Ltd. Pharmaceuticals: MajorHealth Technology Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom. | Corporate Officer/Principal | - |
| AQUESTIVE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| ABEONA THERAPEUTICS INC. | Corporate Officer/Principal | - |
Ausbildung von Eric J. Dadey
| University of Western Kentucky | Graduate Degree |
| University of Kentucky | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ABEONA THERAPEUTICS INC. | Health Technology |
| AQUESTIVE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Atrix Laboratories, Inc.
Atrix Laboratories, Inc. Pharmaceuticals: OtherHealth Technology Atrix Laboratories, Inc. develops and manufactures dental, medical, and veterinary products for drug delivery application | Health Technology |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
TOLMAR Therapeutics, Inc.
 TOLMAR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TOLMAR Therapeutics, Inc. provides healthcare services. The company's products include Eligard, a prostate cancer treatment, Aczone, a dermatology product for the treatment of acne, and Atrigel, a drug delivery system. Its drug delivery systems deliver medicines such as proteins and antibiotics. The company also makes Orajel and Cepacol mouth sore medicines. It is headquartered in Fort Collins, CO. | Health Technology |
| Nycomed Salutar, Inc. | |
Insmed Ltd.
Insmed Ltd. Pharmaceuticals: MajorHealth Technology Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom. | Health Technology |
